133 related articles for article (PubMed ID: 35842839)
1. Identification of potential inhibitors, conformational dynamics, and mechanistic insights into mutant Kirsten rat sarcoma virus (G13D) driven cancers.
Tayubi IA; Kumar S U; Doss C GP
J Cell Biochem; 2022 Sep; 123(9):1467-1480. PubMed ID: 35842839
[TBL] [Abstract][Full Text] [Related]
2. Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D.
Kumar SU; Priya Doss CG
Comput Biol Med; 2021 Dec; 139():104946. PubMed ID: 34715554
[TBL] [Abstract][Full Text] [Related]
3. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach.
Kumar S U; Varghese RP; Preethi VA; Doss CGP; Zayed H
Front Biosci (Landmark Ed); 2023 Nov; 28(11):288. PubMed ID: 38062837
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
[TBL] [Abstract][Full Text] [Related]
5. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
[TBL] [Abstract][Full Text] [Related]
6. CSC01 shows promise as a potential inhibitor of the oncogenic G13D mutant of KRAS: an in silico approach.
Durojaye OA; Ejaz U; Uzoeto HO; Fadahunsi AA; Opabunmi AO; Ekpo DE; Sedzro DM; Idris MO
Amino Acids; 2023 Dec; 55(12):1745-1764. PubMed ID: 37500789
[TBL] [Abstract][Full Text] [Related]
7. New lead compounds identification against KRas mediated cancers through pharmacophore-based virtual screening and in vitro assays.
Ghufran M; Rehman AU; Ayaz M; Ul-Haq Z; Uddin R; Azam SS; Wadood A
J Biomol Struct Dyn; 2023; 41(16):8053-8067. PubMed ID: 36184737
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.
Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A
Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268
[TBL] [Abstract][Full Text] [Related]
9. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
10. Conformational transformation of switch domains in GDP/K-Ras induced by G13 mutants: An investigation through Gaussian accelerated molecular dynamics simulations and principal component analysis.
Chen J; Wang L; Wang W; Sun H; Pang L; Bao H
Comput Biol Med; 2021 Aug; 135():104639. PubMed ID: 34247129
[TBL] [Abstract][Full Text] [Related]
11. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.
Chen CC; Er TK; Liu YY; Hwang JK; Barrio MJ; Rodrigo M; Garcia-Toro E; Herreros-Villanueva M
PLoS One; 2013; 8(2):e55793. PubMed ID: 23437064
[TBL] [Abstract][Full Text] [Related]
12. Distinct dynamics and interaction patterns in H- and K-Ras oncogenic P-loop mutants.
Sayyed-Ahmad A; Prakash P; Gorfe AA
Proteins; 2017 Sep; 85(9):1618-1632. PubMed ID: 28498561
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into non-hotspot KRAS mutations and their potential as targets for effective cancer therapies.
Ding C; Wang G; Zou W; Mao Y; Ma J
J Biomol Struct Dyn; 2024 Mar; ():1-11. PubMed ID: 38486394
[TBL] [Abstract][Full Text] [Related]
14. Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach.
S UK; R B; D TK; Doss CGP; Zayed H
J Biomol Struct Dyn; 2022 Mar; 40(4):1571-1585. PubMed ID: 33034275
[TBL] [Abstract][Full Text] [Related]
15. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
[TBL] [Abstract][Full Text] [Related]
16. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
[TBL] [Abstract][Full Text] [Related]
17. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.
Hocker HJ; Cho KJ; Chen CY; Rambahal N; Sagineedu SR; Shaari K; Stanslas J; Hancock JF; Gorfe AA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10201-6. PubMed ID: 23737504
[TBL] [Abstract][Full Text] [Related]
18. Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect.
He X; Du K; Wang Y; Fan J; Li M; Ni D; Lu S; Bian X; Liu Y
Front Mol Biosci; 2022; 9():860962. PubMed ID: 35463958
[TBL] [Abstract][Full Text] [Related]
19. Quantitative structure-activity relationships analysis, homology modeling, docking and molecular dynamics studies of triterpenoid saponins as Kirsten rat sarcoma inhibitors.
Stitou M; Toufik H; Bouachrine M; Lamchouri F
J Biomol Struct Dyn; 2021 Jan; 39(1):152-170. PubMed ID: 31870215
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of colon cancer K-Ras
Qi Y; Zou H; Zhao X; Kapeleris J; Monteiro M; Li F; Xu ZP; Deng Y; Wu Y; Tang Y; Gu W
Front Pharmacol; 2022; 13():996053. PubMed ID: 36386200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
